R&D at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s R&D?
- Design Therapeutics, Inc. (DSGN) reported R&D of $14.38M in Q1 2026.
- How has Design Therapeutics, Inc.'s R&D changed year-over-year?
- Design Therapeutics, Inc.'s R&D decreased by 6.5% year-over-year, from $15.38M to $14.38M.
- What is the long-term trend for Design Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s R&D has grown at a 24.3% compound annual growth rate (CAGR), from $24.78M to $59.13M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.